Company Name
Anhui Biochem Pharmaceutical Co., Ltd.
Year of Establishment
2002
Company Introduction
Anhui Biochem Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and sales of chemical drugs in the field of antiviral medications for the treatment of diseases such as AIDS and hepatitis B.
The company currently holds 23 drug registration certificates for chemical formulations for the treatment of AIDS, hepatitis B, and other diseases, and has over 20 formulations under research awaiting registration approval.
Adhering to the integrated development concept of “active pharmaceutical ingredients (API) + formulations,” the company possesses the capability for the production and R&D of both APIs and formulations, and has mastered the core technologies of the entire industry chain from APIs to formulations. Some of the company's APIs and formulations have passed the WHO-PQ prequalification, and some API production management has passed the FDA on-site inspection, laying the foundation for the export of the company's products.
The company is committed to the integrated development of APIs and formulations. Its future business development will focus on antiviral drugs, continuously improving the range of generic drugs in the AIDS field, expanding generic drugs for other indications in the antiviral field, and closely following technological trends to conduct innovative drug research and development in areas such as AIDS and hepatitis B. As the company's product line continues to improve, it will accelerate the international registration and market promotion of its drugs, expand product exports, and achieve international development. The company will always take serving the treatment of major national diseases and scientific and technological innovation as its mission, and strive to become an international leading pharmaceutical enterprise in the field of AIDS treatment and other infectious diseases.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Milestone
2002.12 Anhui Biochem Pharm Co., Ltd is established.
2007.03 Lamivudine API has been granted by US FDA (DMF No.20468).
2007.08 Anhui Biochem Pharmaceutical Co., Ltd signs with QVT FUND LP (UK) to establish Anhui Biochem United Pharmaceutical Co., Ltd.
2007.09 Anhui Biochem Pharmaceutical Co., Ltd has established a API manufacturing base at Anhui Taihe Industrial Park.
2008.04 Wholly acquires and establishes subsidiary Anhui Biochem Bio-Pharmaceutical Co., Ltd., and turns the company into a complete industry chain which integrates the intermediate, API and preparation manufacturing and marketing.
2008.05 Lamivudine API has been approved by Health Canada (DMF No. 2008-036).
2008.12 Anhui Biochem United Pharmaceutical has passed the high-tech enterprise certification.
2009.01 The wholly owned subsidiary Anhui Biochem Medical Sales Co., Ltd is established.
2009.03 Anhui Biochem signs Memorandum of Understanding with the Clinton Foundation and has accepted on-site audit for many times.
2018 Some of the company's APIs and formulations have passed the WHO-PQ prequalification.
2019 Some API production management has passed the FDA on-site inspection.
2023 Some API production has been awarded Certificate of Suitability.